Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice
- PMID: 1400564
- PMCID: PMC12201422
- DOI: 10.1007/BF01209486
Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice
Abstract
We have previously shown that Balb/c mice immunised against syngeneic monoclonal antibodies (mAbs), so that they have anti-idiotypic responses against those mAbs, will clear the mAbs from the circulation as a result of immune complex formation. We report here that with three separate mAbs, this clearance of complexes can result in toxicity to the animals. This was particularly severe with one mAb (NCRC-2), in some cases leading to death. It was not seen with Fab/c or Fab fragments of NCRC-2. This toxic response could be passively transferred with serum, indicating that it was due to formation of immune complexes or to their subsequent clearance. Treatment of mice with cobra venom factor, to reduce complement levels, reduced clearance of complexes but had no effect on toxicity. The anti-histamine pyrilamine did not reduce toxicity. This is one of only a few situations in which an anti-(mouse antibody) response has been reported to be potentially dangerous, and is particularly remarkable since it occurs as a result of such a limited anti-antibody response.
Similar articles
-
Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments.J Cancer Res Clin Oncol. 1993;119(7):408-14. doi: 10.1007/BF01218422. J Cancer Res Clin Oncol. 1993. PMID: 8491761 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
-
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2. Cochrane Database Syst Rev. 2018. PMID: 30001476 Free PMC article.
Cited by
-
Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?Eur J Nucl Med. 1995 Jun;22(6):571-80. doi: 10.1007/BF00817285. Eur J Nucl Med. 1995. PMID: 7556306 Review.
References
-
- Azuma J, Kurimoto T, Tsuji S, Mochizuki N, Funjinaga S, Matsumoto Y, Masuho Y (1991) Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother 10:278–285 - PubMed
-
- Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, Clark RE, Waldman TA (1991) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88:2663–2667 - PMC - PubMed
-
- Demignot S, Pimm MV, Baldwin RW (1990) Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in Balb/c mice and nude mice bearing human tumour xenografts. Cancer Res 50:2936–2942 - PubMed
-
- Dillman R (1990) Human antimouse and antiglobulin response to monoclonal antibodies. Antibody Immunoconj Radiopharmacol 3:1–15
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources